I. Smith, M. Procter, R. Gelber, S. Guillaume, A. Feyereislova et al., 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, The Lancet, vol.369, issue.9555, pp.29-36, 2007.
DOI : 10.1016/S0140-6736(07)60028-2

H. Joensuu, P. Kellokumpu-lehtinen, P. Bono, T. Alanko, V. Kataja et al., Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, pp.809-820, 2006.
DOI : 10.1056/NEJMoa053028

A. Prat and J. Baselga, The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2, Nature Clinical Practice Oncology, vol.24, issue.9, pp.531-542, 2008.
DOI : 10.1038/bjc.1992.22

C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris et al., -Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-726, 2002.
DOI : 10.1200/JCO.2002.20.3.719

M. Mano, D. Rosa, D. Azambuja, E. Ismael, G. Durbecq et al., The 17q12-q21 amplicon: Her2 and topoisomerase-II?? and their importance to the biology of solid tumours, Cancer Treatment Reviews, vol.33, issue.1, pp.64-77, 2007.
DOI : 10.1016/j.ctrv.2006.10.001

J. Brase, M. Schmidt, T. Fischbach, H. Sültmann, H. Bojar et al., ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction, Clinical Cancer Research, vol.16, issue.8, pp.2391-2401, 2010.
DOI : 10.1158/1078-0432.CCR-09-2471

E. Arriola, S. Rodriguez-pinilla, M. Lambros, R. Jones, M. James et al., Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer, Breast Cancer Research and Treatment, vol.224, issue.2, pp.181-189, 2007.
DOI : 10.1016/j.canlet.2004.11.007

D. Leo, A. Gancberg, D. Larsimont, D. Tanner, M. Jarvinen et al., HER-2 amplification and topoisomerase II? gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil, Clin Cancer Res, vol.8, pp.1107-1116, 2002.

A. Knoop, H. Knudsen, E. Balslev, B. Rasmussen, J. Overgaard et al., Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group, Journal of Clinical Oncology, vol.23, issue.30, pp.7483-7490, 2005.
DOI : 10.1200/JCO.2005.11.007

M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-lehtinen et al., ???Amplified Breast Cancer: Scandinavian Breast Group Trial 9401, Journal of Clinical Oncology, vol.24, issue.16, pp.2428-2436, 2006.
DOI : 10.1200/JCO.2005.02.9264

J. Coon, E. Marcus, S. Gupta-burt, S. Seelig, K. Jacobson et al., Amplification and overexpression of topoisomerase II? predict response to anthracycline-based therapy in locally advanced breast cancer, Clin Cancer Res, vol.8, pp.1061-1067, 2002.

K. Park, J. Kim, S. Lim, and S. Han, Topoisomerase II-?? (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy, European Journal of Cancer, vol.39, issue.5, pp.631-634, 2003.
DOI : 10.1016/S0959-8049(02)00745-1

B. Ejlertsen, M. Jensen, K. Nielsen, E. Balslev, B. Rasmussen et al., , and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients, Journal of Clinical Oncology, vol.28, issue.6, pp.984-990, 2010.
DOI : 10.1200/JCO.2009.24.1166

O. Malley, F. Chia, S. Tu, D. Shepherd, L. Levine et al., Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, JNCI Journal of the National Cancer Institute, vol.86, issue.3, pp.644-650, 2009.
DOI : 10.1023/B:BREA.0000036783.88387.47

K. Villman, J. Sjöström, R. Heikkilä, R. Hultborn, P. Malmström et al., TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer, Acta Oncologica, vol.39, issue.9, pp.590-596, 2006.
DOI : 10.1016/S0959-8049(03)00265-X

F. Cardoso, V. Durbecq, D. Larsimont, M. Paesmans, J. Leroy et al., Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-?? gene amplification and protein overexpression in locally advanced/metastatic breast cancer, International Journal of Oncology, vol.24, pp.201-209, 2004.
DOI : 10.3892/ijo.24.1.201

T. Järvinen, M. Tanner, V. Rantanen, M. Bärlund, A. Borg et al., Amplification and Deletion of Topoisomerase II?? Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer, The American Journal of Pathology, vol.156, issue.3, pp.839-847, 2000.
DOI : 10.1016/S0002-9440(10)64952-8

G. Konecny, G. Pauletti, M. Untch, H. Wang, V. Möbus et al., Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer, Breast Cancer Research and Treatment, vol.27, issue.26, pp.481-489, 2010.
DOI : 10.1016/S0002-9440(10)64952-8

L. Harris, G. Broadwater, M. Abu-khalaf, D. Cowan, A. Thor et al., Topoisomerase II? amplification does not predict benefit from

. Lamy, 13:R15 http://breast-cancer-research.com/content/13/1/R15 dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013, Breast Cancer Research J Clin Oncol, vol.27, pp.3430-3436, 2009.

R. Tubbs, W. Barlow, G. Budd, E. Swain, P. Porter et al., Status, Journal of Clinical Oncology, vol.27, issue.24, pp.3881-3886, 2009.
DOI : 10.1200/JCO.2008.20.1566

K. Pritchard, H. Messersmith, L. Elavathil, M. Trudeau, O. Malley et al., HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy, Journal of Clinical Oncology, vol.26, issue.5, pp.736-744, 2008.
DOI : 10.1200/JCO.2007.15.4716

D. Slamon and M. Press, Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers, JNCI Journal of the National Cancer Institute, vol.12, issue.8, pp.615-618, 2009.
DOI : 10.1023/A:1011669223035
URL : https://academic.oup.com/jnci/article-pdf/101/9/615/7671610/djp092.pdf

P. Kauraniemi, T. Kuukasjärvi, G. Sauter, and A. Kallioniemi, Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer, The American Journal of Pathology, vol.163, issue.5, pp.1979-1984, 2003.
DOI : 10.1016/S0002-9440(10)63556-0

E. Arriola, C. Marchio, D. Tan, S. Drury, M. Lambros et al., Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines, Laboratory Investigation, vol.115, issue.5, pp.491-503, 2008.
DOI : 10.1042/BJ20050378

A. Shadeo and W. Lam, Comprehensive copy number profiles of breast cancer cell model genomes, Breast Cancer Research, vol.16, issue.1???2, p.9, 2006.
DOI : 10.1093/emboj/16.7.1647
URL : https://breast-cancer-research.biomedcentral.com/track/pdf/10.1186/bcr1370?site=breast-cancer-research.biomedcentral.com

B. Orsetti, M. Nugoli, N. Cervera, L. Lasorsa, P. Chuchana et al., Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes, Cancer Research, vol.64, issue.18, pp.6453-6460, 2004.
DOI : 10.1158/0008-5472.CAN-04-0756
URL : https://hal.archives-ouvertes.fr/inserm-00157287

R. Glynn, N. Miller, and M. Kerin, the pursuit of targeted therapy in breast cancer, Cancer Treat Rev, vol.36, pp.17-29, 2010.

P. Lamy, I. Nanni, F. Fina, F. Bibeau, R. S. Dussert et al., Reliability and Discriminant Validity of HER2 Gene Quantification and Chromosome 17 Aneusomy Analysis by Real-Time PCR in Primary Breast Cancer, The International Journal of Biological Markers, vol.61, issue.1, pp.20-29, 2006.
DOI : 10.1038/modpathol.3880505
URL : https://hal.archives-ouvertes.fr/hal-01823855

F. Baehner, N. Achacoso, T. Maddala, S. Shak, C. Quesenberry et al., Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories, Journal of Clinical Oncology, vol.28, issue.28, pp.4300-4306, 2010.
DOI : 10.1200/JCO.2009.24.8211

T. Susini, C. Bussani, G. Marini, J. Nori, S. Olivieri et al., Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens, Gynecologic Oncology, vol.116, issue.2, pp.234-239, 2010.
DOI : 10.1016/j.ygyno.2009.10.067

S. Vranic, B. Teruya, S. Repertinger, P. Ulmer, J. Hagenkord et al., Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17, Cancer, vol.16, issue.suppl 24, pp.48-53, 2011.
DOI : 10.1097/PDM.0b013e318064c72a

S. Murthy, A. Magliocco, and D. Demetrick, Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase II? genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization, Arch Pathol Lab Med, vol.129, pp.39-46, 2005.

M. Salido, I. Tusquets, J. Corominas, M. Suarez, B. Espinet et al., Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry, Breast Cancer Research, vol.121, issue.2, pp.267-273, 2005.
DOI : 10.1309/FUQH92B039025LHG

J. Bartlett, A. Munro, J. Dunn, C. Mcconkey, S. Jordan et al., Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601), The Lancet Oncology, vol.11, issue.3, pp.266-274, 2010.
DOI : 10.1016/S1470-2045(10)70006-1

R. Ellsworth, D. Ellsworth, H. Patney, B. Deyarmin, B. Love et al., Amplification of HER2 is a marker for global genomic instability, BMC Cancer, vol.10, issue.1, p.297, 2008.
DOI : 10.1093/hmg/10.7.705
URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-8-297?site=bmccancer.biomedcentral.com

K. Nielsen, S. Müller, S. Møller, A. Schønau, E. Balslev et al., genes in breast cancer, Molecular Oncology, vol.25, issue.1, pp.161-168, 2010.
DOI : 10.1200/JCO.2006.09.2775

M. Katoh and M. Katoh, MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain, International Journal of Oncology, vol.22, pp.1369-1374, 2003.
DOI : 10.3892/ijo.22.6.1369

R. Beroukhim, C. Mermel, D. Porter, G. Wei, S. Raychaudhuri et al., The landscape of somatic copy-number alteration across human cancers, Nature, vol.21, issue.7283, pp.899-905, 2010.
DOI : 10.4161/cc.6.6.4035
URL : http://europepmc.org/articles/pmc2826709?pdf=render

Y. Kuwahara, C. Tanabe, T. Ikeuchi, K. Aoyagi, M. Nishigaki et al., Alternative mechanisms of gene amplification in human cancers, Genes, Chromosomes and Cancer, vol.2, issue.2, pp.125-132, 2004.
DOI : 10.1038/19560

K. Kwei, Y. Kung, K. Salari, I. Holcomb, and J. Pollack, Genomic instability in breast cancer: Pathogenesis and clinical implications, Molecular Oncology, vol.276, issue.3, pp.255-266, 2010.
DOI : 10.1016/0165-1110(92)90009-X
URL : https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/j.molonc.2010.04.001

D. Albertson, Gene amplification in cancer, Trends in Genetics, vol.22, issue.8, pp.447-455, 2006.
DOI : 10.1016/j.tig.2006.06.007

D. Leo, A. Desmedt, C. Bartlett, J. Ejlertsen, B. Pritchard et al., Final results of a meta-analysis testing HER2 and topoisomerase II? genes as predictors of incremental benefit from anthracyclines in breast cancer [abstract], J Clin Oncol, issue.15, p.28519, 2010.

D. Leo, A. Biganzoli, L. Claudino, W. Licitra, S. Pestrin et al., Topoisomerase II alpha as a marker predicting anthracyclines??? activity in early breast cancer patients: Ready for the primetime?, European Journal of Cancer, vol.44, issue.18, pp.2791-2798, 2008.
DOI : 10.1016/j.ejca.2008.09.014

M. Press, G. Sauter, M. Buyse, L. Bernstein, R. Guzman et al., Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy, J Clin Oncol, 2010.

Y. Zhu, C. Qi, S. Jain, M. Rao, and J. Reddy, Isolation and Characterization of PBP, a Protein That Interacts with Peroxisome Proliferator-activated Receptor, Journal of Biological Chemistry, vol.9, issue.41, pp.25500-25506, 1997.
DOI : 10.1038/42972
URL : http://www.jbc.org/content/272/41/25500.full.pdf

A. Warnmark, T. Almlof, J. Leers, J. Gustafsson, and E. Treuter, Differential Recruitment of the Mammalian Mediator Subunit TRAP220 by Estrogen Receptors ER?? and ER??, Journal of Biological Chemistry, vol.19, issue.26, pp.23397-23404, 2001.
DOI : 10.1073/pnas.96.7.3999

Q. Wu, R. Burghardt, and S. Safe, Vitamin D-interacting Protein 205 (DRIP205) Coactivation of Estrogen Receptor ?? (ER??) Involves Multiple Domains of Both Proteins, Journal of Biological Chemistry, vol.1, issue.51, pp.53602-53612, 2004.
DOI : 10.1210/me.2002-0351

J. Staaf, G. Jönsson, M. Ringnér, J. Vallon-christersson, D. Grabau et al., High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer, Breast Cancer Research, vol.10, issue.3, p.25, 2010.
DOI : 10.1186/bcr2124

T. Järvinen, M. Tanner, M. Barlund, A. Borg, and J. Isola, Characterization of topoisomerase II? gene amplification and deletion in breast cancer, Genes, Chromosomes and Cancer, vol.79, issue.2, pp.142-150, 1999.
DOI : 10.1038/bjc.1996.647

C. Corzo, B. Bellosillo, J. Corominas, M. Salido, M. Coll et al., Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?, Tumor Biology, vol.7, issue.4, pp.221-228, 2007.
DOI : 10.1002/gcc.20008

F. Esteva and G. Hortobagyi, Topoisomerase II?? Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out, Journal of Clinical Oncology, vol.27, issue.21, pp.3416-3417, 2009.
DOI : 10.1200/JCO.2009.22.6449

S. Paik, J. Bryant, C. Park, B. Fisher, E. Tan-chiu et al., erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.244, issue.3, pp.1361-1370, 1998.
DOI : 10.1126/science.2470152
URL : https://academic.oup.com/jnci/article-pdf/90/18/1361/18048223/90-18-1361.pdf

K. Pritchard, L. Shepherd, O. Malley, F. Andrulis, I. Tu et al., and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, New England Journal of Medicine, vol.354, issue.20, pp.2103-2111, 2006.
DOI : 10.1056/NEJMoa054504

A. Gennari, M. Sormani, P. Pronzato, M. Puntoni, M. Colozza et al., status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials, J Natl Cancer Inst, vol.100, pp.214-234, 2008.

, NCBI Sequence Viewer version 2.10

. Lamy, Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers, Breast Cancer Research, vol.100, issue.15 Suppl, pp.10-1186, 2011.
DOI : 10.1093/jnci/djm252
URL : https://hal.archives-ouvertes.fr/hal-01825781

. Lamy, 13:R15 http://breast-cancer-research.com/content, Breast Cancer Research, vol.131, p.15, 2011.